Cheung Szeya, Bulovic Jennifer, Pillai Ajish, Manoj Trehan, Neeraj Katriyar
Department of Medicine, Long Island Community Hospital, Patchogue, NY, USA.
Gastroenterology and Hepatology, Long Island Community Hospital, Patchogue, NY, USA.
J Community Hosp Intern Med Perspect. 2021 Jan 26;11(1):143-144. doi: 10.1080/20009666.2020.1845929.
This report describes what we believe is the first reported case of clinically significant cholestasis and acute liver injury within three days of meropenem therapy. An 83-year-old Hispanic female was admitted for sepsis of unknown origin and was started on intravenous meropenem. Three days following initiation of the antibiotic, the patient developed mixed hepatocellular and cholestatic liver injury with jaundice and pruritus. Possible causes of cholestasis were excluded after extensive investigations. A drug-induced liver injury was suspected and meropenem was discontinued. Following discontinuation of meropenem, the patient demonstrated symptomatic and laboratory improvements, and her liver enzymes and bilirubin levels were normalized.
本报告描述了我们认为是首例有临床意义的美罗培南治疗三天内出现胆汁淤积和急性肝损伤的病例报告。一名83岁的西班牙裔女性因不明原因的败血症入院,并开始静脉输注美罗培南。使用抗生素三天后,患者出现肝细胞性和胆汁淤积性混合性肝损伤,并伴有黄疸和瘙痒。经过广泛调查,排除了胆汁淤积的可能原因。怀疑是药物性肝损伤,停用了美罗培南。停用美罗培南后,患者症状和实验室检查结果有所改善,肝酶和胆红素水平恢复正常。